



(Incorporated in the Cayman Islands with Limited Liability)

Stock Code: 0575

28 March 2017

ANNOUNCEMENT



Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

OPERATIONS UPDATE MANUFACTURING UPDATE ON FORTACIN™




SUMMARY

This announcement is made by the Company in compliance with the disclosure requirements under Rule 13.09 of the HK Listing Rules and the Inside Information Provisions (as defined under the HK Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

By way of an operations update, the Directors of the Company are pleased to announce that: (i) three (3) GMP batches of the Fortacin™ 12 dose product previously manufactured by PSNW, together with a further variation application to widen the moisture levels permitted in the product during shelf life, received approval from the EMA on 23 March 2017 (communicated to the Company after market close on 24 March 2017), enabling the manufacture and release of EU commercial supplies for launch of Fortacin™, planned by Recordati in late 2017; and (ii) from April 2017, additional manufacturing process development at PSNW will be undertaken with the goal of increasing the commercial batch size for Fortacin™ by approximately threefold, with a view to lowering the unit price and meet the anticipated increase in demand following the EU commercial launch in 2017 by Recordati.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.



This announcement is made by Regent Pacific Group Limited (the “**Company**”) in compliance with the disclosure requirements under Rule 13.09 of The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**HK Listing Rules**”) and the Inside Information Provisions (as defined under the HK Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Manufacturing Update on Fortacin™ Ahead of European Launch

The directors (the “**Directors**” or the “**Board**”) of the Company are pleased to announce that during 2016, in preparation for launch, process validation activities were undertaken at Pharmaserve Northwest Limited’s (“**PSNW**”) commercial facilities and three (3) good manufacturing practice (“**GMP**”) batches of the 12 dose product were manufactured on the commercial manufacturing line. A further variation application to widen the moisture levels permitted in the 12 dose product during shelf life received approval from the European Medicines Agency (“**EMA**”) on 23 March 2017 (communicated to the Company after market close on 24 March 2017). The assessment concluded that widening this parameter has no significant impact on the overall quality of the product. Importantly these activities will enable manufacture and release of EU commercial supplies for launch of Fortacin™, planned by Recordati S.p.A (“**Recordati**”) in late 2017.

Starting from April 2017, additional manufacturing process development at PSNW will be undertaken with the goal of increasing the commercial batch size for Fortacin™ by approximately threefold. The increased number of units produced per batch will offer benefits of a lower unit price and enable the anticipated increase in demand following the EU commercial launch in 2017 by Recordati to be met. It is anticipated that non-GMP development work will be completed at PSNW in Q2 2017, to allow for 3 GMP batches of the 12 dose product to be manufactured on the commercial manufacturing line at the new batch size in Q3 2017. Stability studies will be initiated, with the aim of completing the necessary regulatory submission to EMA in Q1 2018 to register the new batch size.

These are exciting developments as the Company, for and on behalf of Plethora Solutions Limited, pushes ahead with the launch of Fortacin™ in the EU later this year. The Company will continue to keep shareholders and the market more generally updated on key events and milestones as and when they happen or are achieved.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

On Behalf of the Board of
Regent Pacific Group Limited

Jamie Gibson
Director

Directors of the Company:

James Mellon (*Chairman*)^{*}

Jamie Gibson (*Chief Executive Officer*)

David Comba[#]

Julie Oates[#]

Mark Searle[#]

Jayne Sutcliffe^{*}

^{*} *Non-Executive Directors*

[#] *Independent Non-Executive Directors*

Hong Kong, 28 March 2017